ublituximab
Ublituximab is a drug used to treat Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, and other conditions. Ublituximab is being actively studied in 14 studies and prior, has been studied in 9.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| TG Therapeutics, Inc. | TG Therapeutics Investigational Trial Site | Amitkumar Mehta, MD |
| City of Hope Medical Center | City of Hope Medical Center | Jennifer R. Brown, MD, PhD |
| Jennifer R. Brown, MD, PhD | TG Therapeutics RMS Investigational Trial Site | Yazeed Sawalha |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Suspended
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Ublituximab
- Umbralisib
- Aurora, ColoradoUniversity of Colorado Hospital
2022-02-22
Feb 22, 2022C
Not yet recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazemetostat
- +2 more
- Duarte, CaliforniaCity of Hope Medical Center
2022-02-16
Feb 16, 2022W
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Umbralisib
- Ublituximab
- New York, New YorkWeill Cornell Medicine
2022-03-29
Mar 29, 2022T
Active, not recruiting
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
- Ublituximab
- Umbralisib
- Fort Myers, Florida
- +2 more
2022-03-22
Mar 22, 2022C
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
- Duarte, CaliforniaCity of Hope Medical Center
2021-08-10
Aug 10, 2021T
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
- Venetoclax
- +3 more
- Chicago, Illinois
- +2 more
2022-03-22
Mar 22, 2022U
Recruiting
- Mantle Cell Lymphoma
- Ublituximab
- Umbralisib
- Birmingham, AlabamaUniversity of Alabama at Birmingham
2021-09-08
Sep 8, 2021T
Completed
- Chronic Lymphocytic Leukemia
- Richter Syndrome
- Umbralisib
- +2 more
- New York, New York
- +3 more
2021-12-21
Dec 21, 2021T
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ublituximab
- +4 more
- Boston, Massachusetts
- +2 more
2022-03-22
Mar 22, 2022J
Recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
- Boston, Massachusetts
- +2 more
2021-05-10
May 10, 2021Y
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
- Columbus, OhioOhio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022T
Completed
- Relapsing Multiple Sclerosis (RMS)
- Ublituximab
- +3 more
- Phoenix, Arizona
- +12 more
2021-11-11
Nov 11, 2021T
Completed
- Relapsing Multiple Sclerosis (RMS)
- Ublituximab
- +3 more
- Carlsbad, California
- +13 more
2021-11-05
Nov 5, 2021T
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Ublituximab
- +2 more
- Birmingham, Alabama
- +49 more
2022-03-22
Mar 22, 2022T
Completed
- Multiple Sclerosis
- Ublituximab
- Placebo
- Phoenix, Arizona
- +11 more
2021-06-22
Jun 22, 2021T
Recruiting
- B-Cell Lymphoma
- TG-1801
- Ublituximab
- Heidelberg, Victoria, Australia
- +2 more
2022-03-22
Mar 22, 2022T
Recruiting
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- TG-1701
- +2 more
- East Melbourne, Victoria, Australia
- +7 more
2022-03-22
Mar 22, 2022T
Completed
- Non-Hodgkins Lymphoma
- +6 more
- Ublituximab
- Huntsville, Alabama
- +7 more
2019-10-01
Oct 1, 2019J
Completed
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
- Ublituximab
- Baltimore, MarylandJohns Hopkins University School of Medicine
2019-06-05
Jun 5, 2019T
Completed
- Chronic Lymphocytic Leukemia
- Ublituximab
- ibrutinib
- Huntsville, Alabama
- +80 more
2021-12-17
Dec 17, 2021T
Completed
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Ublituximab
- Ibrutinib
- Huntsville, Alabama
- +17 more
2019-10-01
Oct 1, 2019T
Active, not recruiting
- Chronic Lymphocytic Leukemia
- ublituximab
- TGR-1202
- Huntsville, Alabama
- +86 more
2022-03-22
Mar 22, 2022T
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Obinutuzumab
- +3 more
- Huntsville, Alabama
- +153 more
2022-03-22
Mar 22, 2022T
Active, not recruiting
- Diffuse Large B-Cell Lymphoma
- +4 more
- Ublituximab
- +2 more
- Birmingham, Alabama
- +167 more
2022-03-22
Mar 22, 2022T
Completed
- Non-Hodgkins Lymphoma
- +6 more
- Ublituximab
- Lenalidomide
- Huntsville, Alabama
- +1 more
2014-10-09
Oct 9, 2014